<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888797</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-6994-OZ-CTIL</org_study_id>
    <nct_id>NCT00888797</nct_id>
  </id_info>
  <brief_title>β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence</brief_title>
  <official_title>Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colon and rectal cancer is the second most prevalent malignant disease in the western world,&#xD;
      causing significant morbidity, mortality, and healthcare sources use. Treating colon and&#xD;
      rectal cancer with curative intent generally includes resection of the primary tumor. Despite&#xD;
      its crucial role, surgery by itself induce physiological changes resulting in significant&#xD;
      immune depression and other physiological perturbations, which may in turn play a significant&#xD;
      role in the initiation of new metastases and the progression of pre-existing dormant&#xD;
      metastases. The aim of this study is to assess the use of perioperative medical intervention&#xD;
      using a combination of a β-adrenergic blocker (Propranolol) and a COX2 inhibitor (Etodolac),&#xD;
      in order to attenuate the surgically induced immunosuppression and other physiological&#xD;
      perturbations, aiming to reduce the rate of tumor recurrence and distant metastatic disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrent and metastatic cancer</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>magnitude and duration of surgically induced immune depression, as reflected in the blood samples</measure>
    <time_frame>early postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early postoperative morbidity and mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perioperative Propranolol and Etodolac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol and Etodolac</intervention_name>
    <description>Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients planned for surgery for primary resection of colon and rectal cancer in&#xD;
             curative intent.&#xD;
&#xD;
          -  Single colonic or rectal carcinoma, proofed by full colonoscopy and tumor biopsy. If&#xD;
             colonoscopy failed to reach the cecum, proximal colonic investigation will be made&#xD;
             using contract enema or CT colonography.&#xD;
&#xD;
          -  No evidence of metastatic disease prior to surgery. Minimal workup would include&#xD;
             abdominal CT with IV contrast (or CT+liver US) and chest XR.&#xD;
&#xD;
          -  Age between 18 and 75 year old.&#xD;
&#xD;
          -  ASA score of 1-3&#xD;
&#xD;
          -  The patient is able to understand the study objectives and procedures, able to comply&#xD;
             with the protocol, and is capable to sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic disease, known prior to surgery.&#xD;
&#xD;
          -  Patients in whom metastatic disease is found at surgery will complete the intervention&#xD;
             phase, followed for additional month for potential complications, and will exit the&#xD;
             study to allow potential participation in further clinical trials.&#xD;
&#xD;
          -  Patients in whom surgical resection is planned without curative intent.&#xD;
&#xD;
          -  Patients with renal failure, measured by Creatinine level &gt;1.5&#xD;
&#xD;
          -  Patients with significant heart failure (NYH 3 or higher)&#xD;
&#xD;
          -  Patients with significant liver failure (known cirrhosis, Bilirubin level&gt;2)&#xD;
&#xD;
          -  Patients suffering from asthma&#xD;
&#xD;
          -  Patients with known allergy to one or more of the study medications&#xD;
&#xD;
          -  Patients with known allergy to any medication from the non-steroidal anti-inflammatory&#xD;
             drug group.&#xD;
&#xD;
          -  Patients with diabetes (type 1 or 2).&#xD;
&#xD;
          -  Patients treated chronically with one or more of the study medications&#xD;
&#xD;
          -  Patients treated chronically with any type of Beta adrenergic blocker.&#xD;
&#xD;
          -  Patients treated chronically with any type of COX inhibitor.&#xD;
&#xD;
          -  Patients with second or third degree AV block.&#xD;
&#xD;
          -  Patients with sinus bradycardia (patients with heart rate of less than 50).&#xD;
&#xD;
          -  Patients with sick sinus syndrome.&#xD;
&#xD;
          -  Patients with Prinzmetal's angina&#xD;
&#xD;
          -  Patients with right sided heart failure owing to pulmonary hypertension.&#xD;
&#xD;
          -  Patients with significant cardiomegaly&#xD;
&#xD;
          -  Patients with (current) pheochromocytoma&#xD;
&#xD;
          -  Patients with chronic Digoxin treatment&#xD;
&#xD;
          -  Patients with active peptic disease&#xD;
&#xD;
          -  Patients with peripheral vascular disease&#xD;
&#xD;
          -  Patients with history or concomitant malignant disease of any type.&#xD;
&#xD;
          -  Patients who were treated with chemotherapy in the last 10 years for any reason&#xD;
             besides neo-adjuvant therapy for rectal cancer within the last six months.&#xD;
&#xD;
          -  Pregnant woman.&#xD;
&#xD;
          -  Patients participating in any other clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oded Zmora, M.D.</last_name>
    <phone>972-3-5302247</phone>
    <email>ozmora@post.post.tau.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin- Beilinson Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nir Wasserberg, M.D.</last_name>
      <email>nirw@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Nir Wasserberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv-Sourasky Medical Center</name>
      <address>
        <city>Tal Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hagit Tulchinsky, M.D.</last_name>
      <email>hagitt@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Hagit Tulchinsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>45858</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oded Zmora, M.D.</last_name>
      <phone>972-3-5302247</phone>
      <email>ozmora@post.tau.ac.il</email>
    </contact>
    <investigator>
      <last_name>Oded Zmora, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marat Khaikin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>April 26, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>July 10, 2011</last_update_submitted>
  <last_update_submitted_qc>July 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Oded Zmora, MD, Deparetment of Surgery</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etodolac</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

